{"id":73617,"date":"2025-09-23T08:38:28","date_gmt":"2025-09-23T08:38:28","guid":{"rendered":"https:\/\/leitat.org\/?p=73617"},"modified":"2025-09-23T08:52:13","modified_gmt":"2025-09-23T08:52:13","slug":"proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer","status":"publish","type":"post","link":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/","title":{"rendered":"Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"73617\" class=\"elementor elementor-73617\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4c3e2f6 e-flex e-con-boxed e-con e-parent\" data-id=\"4c3e2f6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-fa563ed elementor-widget elementor-widget-text-editor\" data-id=\"fa563ed\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span data-contrast=\"auto\">La inmunoterapia contra el c\u00e1ncer, tambi\u00e9n conocida como inmuno-oncolog\u00eda, representa una de las mayores revoluciones en el tratamiento oncol\u00f3gico en las \u00faltimas d\u00e9cadas. Esta estrategia terap\u00e9utica utiliza el sistema inmunol\u00f3gico del propio paciente para prevenir, controlar y eliminar tumores, ofreciendo alternativas m\u00e1s espec\u00edficas y menos t\u00f3xicas que los tratamientos tradicionales. Dentro de las m\u00faltiples modalidades de inmunoterapia se encuentran los anticuerpos dirigidos, las vacunas contra el c\u00e1ncer, la transferencia adoptiva de c\u00e9lulas, los virus oncol\u00edticos, los inhibidores de puntos de control inmunitario, las citocinas y los adyuvantes.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p><p><span data-contrast=\"auto\">En este marco, el proyecto <\/span><b><span data-contrast=\"auto\">HPK1-INHIB<\/span><\/b><span data-contrast=\"auto\"> se enfoca en el descubrimiento y desarrollo inicial de un nuevo inhibidor covalente de la quinasa progenitora hematopoy\u00e9tica 1 (HPK1), una prote\u00edna que act\u00faa como reguladora negativa en la se\u00f1alizaci\u00f3n de c\u00e9lulas T y B. Al bloquear las se\u00f1ales inhibitorias mediadas por HPK1, estos nuevos compuestos potencian la capacidad de las c\u00e9lulas T para atacar y eliminar c\u00e9lulas tumorales, convirti\u00e9ndose en un prometedor objetivo para la inmunoterapia antitumoral.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p><p><span data-contrast=\"auto\">Este ambicioso proyecto es llevado a cabo por un consorcio p\u00fablico-privado integrado por la empresa <\/span><i><span data-contrast=\"auto\">biotech<\/span><\/i> <b><span data-contrast=\"auto\">Medchemfarma<\/span><\/b> <b><span data-contrast=\"auto\">SL<\/span><\/b><span data-contrast=\"auto\"> y los centros de investigaci\u00f3n <\/span><b><span data-contrast=\"auto\">Universidad de Santiago de Compostela (USC)<\/span><\/b><span data-contrast=\"auto\"> y <strong>Leitat<\/strong><\/span><span data-contrast=\"auto\">. La colaboraci\u00f3n interdisciplinaria ha permitido avanzar en el dise\u00f1o, s\u00edntesis, optimizaci\u00f3n y desarrollo precl\u00ednico de inhibidores de la enzima HPK1 con miras a su futura evaluaci\u00f3n cl\u00ednica.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p><p><span data-contrast=\"auto\">Adem\u00e1s de su impacto directo en mejorar la salud y calidad de vida de los pacientes con c\u00e1ncer, este proyecto tiene un gran potencial socioecon\u00f3mico, ya que podr\u00eda reducir los costes asociados a las terapias actuales y ofrecer nuevas opciones m\u00e1s eficaces y accesibles para el tratamiento oncol\u00f3gico.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p><p>\u00a0<\/p><p><span class=\"TextRun SCXW195996532 BCX8\" lang=\"ES-ES\" xml:lang=\"ES-ES\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW195996532 BCX8\" data-ccp-parastyle=\"No Spacing\">Proyecto CPP2022-009716 financiado por:<\/span><\/span><span class=\"EOP SCXW195996532 BCX8\" data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-dc7694d e-flex e-con-boxed e-con e-parent\" data-id=\"dc7694d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-22bd3e0 elementor-widget elementor-widget-image\" data-id=\"22bd3e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"387\" height=\"71\" src=\"https:\/\/leitat.org\/wp-content\/uploads\/2023\/05\/Imagen2.png\" class=\"attachment-large size-large wp-image-72453\" alt=\"\" srcset=\"https:\/\/leitat.org\/wp-content\/uploads\/2023\/05\/Imagen2.png 387w, https:\/\/leitat.org\/wp-content\/uploads\/2023\/05\/Imagen2-300x55.png 300w\" sizes=\"(max-width: 387px) 100vw, 387px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>La inmunoterapia contra el c\u00e1ncer, tambi\u00e9n conocida como inmuno-oncolog\u00eda, representa una de las mayores revoluciones en el tratamiento oncol\u00f3gico en las \u00faltimas d\u00e9cadas. Esta estrategia terap\u00e9utica utiliza el sistema inmunol\u00f3gico del propio paciente para prevenir, controlar y eliminar tumores, ofreciendo alternativas m\u00e1s espec\u00edficas y menos t\u00f3xicas que los tratamientos tradicionales. Dentro de las m\u00faltiples modalidades [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":73618,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[13,14],"tags":[206],"class_list":["post-73617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aei","category-health-technologies","tag-noticias-blog"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer - Leitat Technological Center<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer - Leitat Technological Center\" \/>\n<meta property=\"og:description\" content=\"La inmunoterapia contra el c\u00e1ncer, tambi\u00e9n conocida como inmuno-oncolog\u00eda, representa una de las mayores revoluciones en el tratamiento oncol\u00f3gico en las \u00faltimas d\u00e9cadas. Esta estrategia terap\u00e9utica utiliza el sistema inmunol\u00f3gico del propio paciente para prevenir, controlar y eliminar tumores, ofreciendo alternativas m\u00e1s espec\u00edficas y menos t\u00f3xicas que los tratamientos tradicionales. Dentro de las m\u00faltiples modalidades [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Leitat Technological Center\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T08:38:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-23T08:52:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Dissemination Manager\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dissemination Manager\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/\"},\"author\":{\"name\":\"Dissemination Manager\",\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/person\/00bc0fc5cc4e098e7d903185a43a9ca2\"},\"headline\":\"Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer\",\"datePublished\":\"2025-09-23T08:38:28+00:00\",\"dateModified\":\"2025-09-23T08:52:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/\"},\"wordCount\":322,\"publisher\":{\"@id\":\"https:\/\/leitat.org\/es\/#organization\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png\",\"keywords\":[\"Noticias Blog\"],\"articleSection\":[\"AEI\",\"Health technologies\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/\",\"url\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/\",\"name\":\"Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer - Leitat Technological Center\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png\",\"datePublished\":\"2025-09-23T08:38:28+00:00\",\"dateModified\":\"2025-09-23T08:52:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#primaryimage\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png\",\"width\":1200,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"HOME\",\"item\":\"https:\/\/leitat.org\/es\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health technologies\",\"item\":\"https:\/\/leitat.org\/es\/blog\/category\/health-technologies\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/leitat.org\/es\/#website\",\"url\":\"https:\/\/leitat.org\/es\/\",\"name\":\"Leitat Technological Center\",\"description\":\"Managing Technologies\",\"publisher\":{\"@id\":\"https:\/\/leitat.org\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/leitat.org\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/leitat.org\/es\/#organization\",\"name\":\"Leitat Technological Center\",\"url\":\"https:\/\/leitat.org\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"width\":226,\"height\":78,\"caption\":\"Leitat Technological Center\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/person\/00bc0fc5cc4e098e7d903185a43a9ca2\",\"name\":\"Dissemination Manager\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g\",\"caption\":\"Dissemination Manager\"},\"sameAs\":[\"https:\/\/leitat.org\"],\"url\":\"https:\/\/leitat.org\/es\/blog\/author\/editor-wp\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer - Leitat Technological Center","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"es_ES","og_type":"article","og_title":"Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer - Leitat Technological Center","og_description":"La inmunoterapia contra el c\u00e1ncer, tambi\u00e9n conocida como inmuno-oncolog\u00eda, representa una de las mayores revoluciones en el tratamiento oncol\u00f3gico en las \u00faltimas d\u00e9cadas. Esta estrategia terap\u00e9utica utiliza el sistema inmunol\u00f3gico del propio paciente para prevenir, controlar y eliminar tumores, ofreciendo alternativas m\u00e1s espec\u00edficas y menos t\u00f3xicas que los tratamientos tradicionales. Dentro de las m\u00faltiples modalidades [&hellip;]","og_url":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/","og_site_name":"Leitat Technological Center","article_published_time":"2025-09-23T08:38:28+00:00","article_modified_time":"2025-09-23T08:52:13+00:00","og_image":[{"width":1200,"height":700,"url":"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png","type":"image\/png"}],"author":"Dissemination Manager","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Dissemination Manager","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#article","isPartOf":{"@id":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/"},"author":{"name":"Dissemination Manager","@id":"https:\/\/leitat.org\/es\/#\/schema\/person\/00bc0fc5cc4e098e7d903185a43a9ca2"},"headline":"Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer","datePublished":"2025-09-23T08:38:28+00:00","dateModified":"2025-09-23T08:52:13+00:00","mainEntityOfPage":{"@id":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/"},"wordCount":322,"publisher":{"@id":"https:\/\/leitat.org\/es\/#organization"},"image":{"@id":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png","keywords":["Noticias Blog"],"articleSection":["AEI","Health technologies"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/","url":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/","name":"Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer - Leitat Technological Center","isPartOf":{"@id":"https:\/\/leitat.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#primaryimage"},"image":{"@id":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png","datePublished":"2025-09-23T08:38:28+00:00","dateModified":"2025-09-23T08:52:13+00:00","breadcrumb":{"@id":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#primaryimage","url":"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png","width":1200,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/leitat.org\/es\/blog\/proyecto-hpk1-inhib-innovacion-en-inmunoterapia-contra-el-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"HOME","item":"https:\/\/leitat.org\/es\/home\/"},{"@type":"ListItem","position":2,"name":"Health technologies","item":"https:\/\/leitat.org\/es\/blog\/category\/health-technologies\/"},{"@type":"ListItem","position":3,"name":"Proyecto HPK1-INHIB: Innovaci\u00f3n en inmunoterapia contra el c\u00e1ncer"}]},{"@type":"WebSite","@id":"https:\/\/leitat.org\/es\/#website","url":"https:\/\/leitat.org\/es\/","name":"Leitat Technological Center","description":"Managing Technologies","publisher":{"@id":"https:\/\/leitat.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/leitat.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/leitat.org\/es\/#organization","name":"Leitat Technological Center","url":"https:\/\/leitat.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","width":226,"height":78,"caption":"Leitat Technological Center"},"image":{"@id":"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/leitat.org\/es\/#\/schema\/person\/00bc0fc5cc4e098e7d903185a43a9ca2","name":"Dissemination Manager","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g","caption":"Dissemination Manager"},"sameAs":["https:\/\/leitat.org"],"url":"https:\/\/leitat.org\/es\/blog\/author\/editor-wp\/"}]}},"_links":{"self":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts\/73617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/comments?post=73617"}],"version-history":[{"count":7,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts\/73617\/revisions"}],"predecessor-version":[{"id":73632,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts\/73617\/revisions\/73632"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/media\/73618"}],"wp:attachment":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/media?parent=73617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/categories?post=73617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/tags?post=73617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}